GPCR STRUCTURE THERAPEUTICS

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.

Guggenheim SMID Cap Biotech Conference

 Format:Fireside chat and 1x1 meetings
 Date/time:Wednesday, February 5 at 10:30 a.m. ET
 Location:New York, NY
 Webcast link:
   

Leerink Global Healthcare Conference

 Format:Fireside chat and 1x1 meetings
 Date/time:Monday, March 10 at 1:00 p.m. ET
 Location:Miami, FL
 Webcast link:
   

Jefferies Biotech on the Bay Summit

 Format:1x1 meetings
 Date:Tuesday, March 11
 Location:Miami, FL
   

The live and archived webcasts of the fireside chats will be accessible from the company’s website at and replays will be available for 90 days.

About Structure Therapeutics 

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit .

Investors:

Danielle Keatley

Structure Therapeutics Inc.

Media:

Dan Budwick

1AB



EN
30/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRUCTURE THERAPEUTICS

 PRESS RELEASE

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Finan...

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Structure Therapeuti...

 PRESS RELEASE

Structure Therapeutics to Participate in Multiple Upcoming Healthcare ...

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference  Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York...

 PRESS RELEASE

Structure Therapeutics Announces Selection of Lead Oral Small Molecule...

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NA...

 PRESS RELEASE

Structure Therapeutics Reports Third Quarter 2024 Financial Results an...

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ...

 PRESS RELEASE

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCE...

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch